Pontine Glioma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Pontine Glioma – Pipeline Review, H2 2017’, provides an overview of the Pontine Glioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pontine Glioma

The report reviews pipeline therapeutics for Pontine Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pontine Glioma therapeutics and enlists all their major and minor projects

The report assesses Pontine Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pontine Glioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pontine Glioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pontine Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Arog Pharmaceuticals Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Burzynski Research Institute Inc

Celgene Corp

Insys Therapeutics Inc

Loxo Oncology Inc

Medicenna Therapeutics Corp

Midatech Pharma Plc

Moleculin Biotech Inc

Novartis AG

Novogen Ltd

Ono Pharmaceutical Co Ltd

Pfizer Inc

Sanofi

Sumitomo Dainippon Pharma Co Ltd

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pontine Glioma - Overview 8

Pontine Glioma - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Pontine Glioma - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Pontine Glioma - Companies Involved in Therapeutics Development 25

AbbVie Inc 25

Arog Pharmaceuticals Inc 25

AstraZeneca Plc 26

Boehringer Ingelheim GmbH 26

Bristol-Myers Squibb Co 26

Burzynski Research Institute Inc 27

Celgene Corp 27

Insys Therapeutics Inc 28

Loxo Oncology Inc 28

Medicenna Therapeutics Corp 29

Midatech Pharma Plc 29

Moleculin Biotech Inc 30

Novartis AG 30

Novogen Ltd 30

Ono Pharmaceutical Co Ltd 31

Pfizer Inc 31

Sanofi 32

Sumitomo Dainippon Pharma Co Ltd 32

ZIOPHARM Oncology Inc 33

Pontine Glioma - Drug Profiles 34

8H-9 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

A-10 + AS-21 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

AdRTSIL-12 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

afatinib dimaleate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

AZD-1775 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

cabazitaxel - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

cannabidiol - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

crenolanib besylate - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

depatuxizumab mafodotin - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

DNX-2401 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

elatipepimut-S + adegrapepimut-S - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

ipilimumab + nivolumab - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

larotrectinib - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

MDNA-55 - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

MTX-110 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

nivolumab - Drug Profile 109

R&D Progress 110

ORX-101 - Drug Profile 160

Product Description 160

Mechanism Of Action 160

R&D Progress 160

p28 - Drug Profile 161

Product Description 161

Mechanism Of Action 161

R&D Progress 161

panobinostat - Drug Profile 163

Product Description 163

Mechanism Of Action 163

R&D Progress 163

pidilizumab - Drug Profile 170

Product Description 170

Mechanism Of Action 170

R&D Progress 170

pomalidomide - Drug Profile 173

Product Description 173

Mechanism Of Action 173

R&D Progress 173

Trilexium - Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

Vaccine for Pontine Glioma - Drug Profile 183

Product Description 183

Mechanism Of Action 183

R&D Progress 183

WP-1066 - Drug Profile 184

Product Description 184

Mechanism Of Action 184

R&D Progress 184

Pontine Glioma - Dormant Projects 186

Pontine Glioma - Product Development Milestones 187

Featured News & Press Releases 187

Oct 16, 2017: ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors 187

Jun 26, 2017: Moleculin Announces Scientific Support for Research Endeavor at Mayo Clinic 187

Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) 188

Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 188

Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier 189

May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells 189

Appendix 191

Methodology 191

Coverage 191

Secondary Research 191

Primary Research 191

Expert Panel Validation 191

Contact Us 191

Disclaimer 192

List of Tables

List of Tables

Number of Products under Development for Pontine Glioma, H2 2017 9

Number of Products under Development by Companies, H2 2017 11

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Universities/Institutes, H2 2017 16

Number of Products by Stage and Target, H2 2017 18

Number of Products by Stage and Mechanism of Action, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pontine Glioma – Pipeline by AbbVie Inc, H2 2017 25

Pontine Glioma – Pipeline by Arog Pharmaceuticals Inc, H2 2017 25

Pontine Glioma – Pipeline by AstraZeneca Plc, H2 2017 26

Pontine Glioma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 26

Pontine Glioma – Pipeline by Bristol-Myers Squibb Co, H2 2017 27

Pontine Glioma – Pipeline by Burzynski Research Institute Inc, H2 2017 27

Pontine Glioma – Pipeline by Celgene Corp, H2 2017 28

Pontine Glioma – Pipeline by Insys Therapeutics Inc, H2 2017 28

Pontine Glioma – Pipeline by Loxo Oncology Inc, H2 2017 29

Pontine Glioma – Pipeline by Medicenna Therapeutics Corp, H2 2017 29

Pontine Glioma – Pipeline by Midatech Pharma Plc, H2 2017 29

Pontine Glioma – Pipeline by Moleculin Biotech Inc, H2 2017 30

Pontine Glioma – Pipeline by Novartis AG, H2 2017 30

Pontine Glioma – Pipeline by Novogen Ltd, H2 2017 31

Pontine Glioma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 31

Pontine Glioma – Pipeline by Pfizer Inc, H2 2017 32

Pontine Glioma – Pipeline by Sanofi, H2 2017 32

Pontine Glioma – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 33

Pontine Glioma – Pipeline by ZIOPHARM Oncology Inc, H2 2017 33

Pontine Glioma – Dormant Projects, H2 2017 186

List of Figures

List of Figures

Number of Products under Development for Pontine Glioma, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products by Top 10 Targets, H2 2017 17

Number of Products by Stage and Top 10 Targets, H2 2017 17

Number of Products by Top 10 Mechanism of Actions, H2 2017 19

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports